Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: Subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China)

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 99-105

  Wang, Fan ^a   Ye, Ping ^a   Hu, Dayi ^b   Min, Ying ^a   Zhao, Shuiping ^c   Wang, Yongjun ^d   Mu, Yiming ^a   Yan, Xiaowei ^e   Li, Zhanquan ^f   Wei, Yidong ^g   Li, Jihu ^h  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f People's Hospital of Liaoning Province   (China)

^g TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^h MSD China Holding Co   (China)

Author keywords

Anticholesteremic agents; Dyslipidemia; Goal attainment; LDL cholesterol; Metabolic syndrome; Non HDL cholesterol

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; XUEZHIKANG; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHINA; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; AGED; ANTHROPOMETRY; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIAS; ETHNOLOGY; INTERNATIONAL COOPERATION; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; RISK FACTOR; SMOKING;

AGED; ANTHROPOMETRY; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHINA; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; SMOKING;

EID: 84907706509     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.023     Document Type: Article

References (26)

1. Samson S.L., Garber A.J. Metabolic syndrome. Endocrinol Metab Clin North Am 2014, 43(1):1-23.
2. Del Brutto O.H., Zambrano M., Peñaherrera E., Montalván M., Pow-Chon-Long F., Tettamanti D. Prevalence of the metabolic syndrome and its correlation with the cardiovascular health status in stroke- and ischemic heart disease-free Ecuadorian natives/mestizos aged ≥40 years living in Atahualpa: a population-based study. Diabetes Metab Syndr 2013, 7(4):218-222.
3. Sheikhbahaei S., Fotouhi A., Hafezi-Nejad N., Nakhjavani M., Esteghamati A. Serum uric Acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord 2014, 12(2):102-109.
4. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. JAm Coll Cardiol 2007, 49(4):403-414.
5. Ng D.S. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets. Can J Diabetes 2013, 37(5):319-326.
6. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2011, 32(14):1769-1818.
7. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An international atherosclerosis society position paper: global recommendations for themanagement of dyslipidemia-full report. JClin Lipidol 2014, 8(1):29-60.
8. Sharma M., Ansari M.T., Abou-Setta A.M., Soares-Weiser K., Ooi T.C., Sears M., et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009, 151(9):622-630.
9. LaRosa J.C., Deedwania P.C., Shepherd J., Wenger N.K., Greten H., DeMicco D.A., et al. TNT Investigators. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the treating to new targets [TNT] trial). Am J Cardiol 2010, 105(3):283-287.
10. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Coordinating committee of the national cholesterol education program. Implications of recent clinica I trials for the national cholesterol education program adult treatment panel III guidelines. JAm Coll Cardiol 2004, 44(3):720-732.
11. Expert Dyslipidemia Panel Grundy SM. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. JClin Lipidol 2013, 7(6):561-565.
12. Zhao S., Wang Y., Mu Y., Yu B., Ye P., Yan X., et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 2014, 235(2):463-469.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 2002, 106(25):3143-3421.
14. Hu D.Y., Ding R.J. Guidelines for management of adult dyslipidemia in China. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35(5):390-410.
15. Phan B.A., Toth P.P. Dyslipidemia in women: etiology and management. Int J Womens Health 2014, 6:185-194.
16. Guyton J.R., Slee A.E., Anderson T., Fleg J.L., Goldberg R.B., Kashyap M.L., et al. Relationship of lipoproteins to cardiovascular events: the aim-high trial (atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides and impact on global health outcomes). JAm Coll Cardiol 2013, 62(17):1580-1584.
17. Klop B., Elte J.W., Cabezas M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5(4):1218-1240.
18. Jacobson T.A. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Int J Clin Pract 2011, 65(1):82-101.
19. Stone N.J., Robinson J., Lichtenstein A.H., Merz NB C., Blum C.B., et al. Cardiovascular risk in adults: a report of the American college of cardiology/American 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic heart association Task Force on practice guidelines. Circulation 2014, 129(25 Suppl.2):S1-S45.
20. NLA Expert Panel Members. NLA recommendations for patient-centered management of dyslipidemia. http://https://www.lipid.org/util/comments/getpdf_final.php.
21. Koh K.K., Sakuma I., Quon M.J. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215(1):1-8.
22. Oda E., Kawai R., Sukumaran V., Watanabe K. LDL cholesterol is more strongly associated with metabolic syndrome in Japanese women than in men. Intern Med 2009, 48:1607-1614.
23. Ilanne-Parikka P., Eriksson J.G., Lindström J., Hämäläinen H., Keinänen-Kiukaanniemi S., Laakso M., et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the diabetes prevention study cohort. Diabetes Care 2004, 27(9):2135-2140. Finnish Diabetes Prevention Study Group.
24. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291. HPS2-THRIVE Collaborative Group.
25. Ginsberg H.N. The ACCORD (action to control cardiovascular risk in diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care 2011, 2(34Suppl.):S107-S108.
26. Fruchart J.C., Davignon J., Hermans M.P., Al-Rubeaan K., Amarenco P., Assmann G., et al. Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol 2014, 24(13):26.